The company said Jos Almeida stepped down as Chair, President and Chief Executive Officer on February 3, 2025 and will serve in an advisory capacity through October 31, 2025. In the same announcement, it said Brent Shafer was named Chair and Interim CEO and Heather Knight was named Chief Operating Officer.

1. 01

   The company said Jos Almeida stepped down as Chair, President and Chief Executive Officer on February 3, 2025 and will serve in an advisory capacity through October 31, 2025. In the same announcement, it said Brent Shafer was named Chair and Interim CEO and Heather Knight was named Chief Operating Officer.

2. 02

   Baxter said it completed the sale of its Kidney Care business, now known as Vantive, to Carlyle on January 31, 2025, with net after-tax proceeds of about $3.4 billion. The company said it completed all of the strategic initiatives it announced in January 2023.

3. 03

   Baxter said its FY 2024 revenue, excluding Discontinued Operations, was $10.6B, with segment shares of 49%, 28%, 23% and 1% below. It said it has about 38,000 employees and products in more than 100 countries.

4. 04

   The company said 9 of its 10 directors are independent and the average tenure is about 4 years. It said it first reached out to about 50% of outstanding shares during its stockholder outreach from 2023 to 2024, and that directors or management met with about 35% of outstanding shares.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.